Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Sophia Hober

KTH Royal Institute of Technology

Sweden

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Academic Page

Research Interests

Immunology

50%

Virology

60%

Biopharmaceutics

40%

Vaccinology

40%

Targeted Therapy

30%

Sars-cov-2

30%

Protein Engineering

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles18

Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden.

Article Link

Year:

2024

Evaluation of Approaches for the Assessment of HER2 Expression in Breast Cancer by Radionuclide Imaging Using the Scaffold Protein [99mTc]Tc-ADAPT6

Article Link

Year:

2024

Targeted HER2-positive cancer therapy using ADAPT6 fused to horseradish peroxidase

Article Link

Year:

2024

Cooperative Folding as a Molecular Switch in an Evolved Antibody Binder

Article Link

Year:

2024

Fast and robust recombinant protein production utilizing episomal stable pools in WAVE bioreactors

Article Link

Year:

2024

Distinct roles of vaccine-induced SARS-CoV-2-specific neutralizing antibodies and T cells in protection and disease

Article Link

Year:

2024

Direct Intra-Patient Comparison of Scaffold Protein-Based Tracers, [99mTc]Tc-ADAPT6 and [99mTc]Tc-(HE)3-G3, for Imaging of HER2-Positive Breast Cancer

Article Link

Year:

2023

The GRPR Antagonist [99mTc]Tc-maSSS-PEG2-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity

Article Link

Year:

2023

Calcium-dependent affinity ligands for the purification of antibody fragments at neutral pH

Article Link

Year:

2023

An easy-to-use high-throughput selection system for the discovery of recombinant protein binders from alternative scaffold libraries

Article Link

Year:

2023

Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose

Article Link

Year:

2023

Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines

Article Link

Year:

2022

Impact of SARS‐CoV‐2 infection on vaccine‐induced immune responses over time

Article Link

Year:

2022

Direct In Vivo Comparison of 99mTc-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy

Article Link

Year:

2022

Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart

Article Link

Year:

2022

Integrated continuous biomanufacturing on pilot scale for acid‐sensitive monoclonal antibodies

Article Link

Year:

2022

B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patients.

Article Link

Year:

2022

Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein

Article Link

Year:

2021

Collaborators14

Soo Aleman

Karolinska Institutet

SWEDEN

Mikael Åberg

Associate professor

Uppsala University

SWEDEN

Vladimir Tolmachev

Uppsala University

SWEDEN

Torbjörn Gräslund

KTH Royal Institute of Technology

SWEDEN

Anna Orlova

Uppsala University

SWEDEN

Anna Pasetto

University of Oslo

NORWAY

Sebastian Havervall

Karolinska Institutet

SWEDEN

Anzhelika Vorobyeva

Uppsala University

SWEDEN

Lars Frelin

Karolinska Institutet

SWEDEN

Haozhong Ding

KTH Royal Institute of Technology

SWEDEN

Emma Von Witting

KTH Royal Institute of Technology

SWEDEN

Jonas Klingstrom

Karolinska Institutet

SWEDEN

Sara Mangsbo

Professor

Uppsala University

SWEDEN

Hubert Schwarz

KTH Royal Institute of Technology

SWEDEN

How do I reach out?

Meet Kite AI